Back to Search
Start Over
The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders
- Source :
- Thrombosis research. 135(2)
- Publication Year :
- 2014
-
Abstract
- Cardiovascular disease (CVD) includes a number of conditions such as myocardial infarction, coronary heart disease, stroke, and venous thromboembolism. CVD is a leading health problem worldwide and a major cause of mortality, morbidity, and disability; it is also associated with high healthcare costs. The incidence of CVD is predicted to increase in the forthcoming years, and thus it is crucial that physicians are aware of the benefits and limitations of the available therapies to ensure patients receive optimized treatment. Current clinical practice guidelines provide recommendations on the use of anticoagulants and antiplatelets for both the prevention and treatment of CVD. Aspirin is the most studied antiplatelet agent in this context. The benefits of aspirin are well documented and supported by data from robust clinical trials for CVD conditions, such as acute coronary syndrome and stroke prevention in patients with atrial fibrillation. However, the clinical benefits of aspirin are less clear for other conditions, namely for primary prevention of venous thromboembolism after major orthopaedic surgery, particularly in comparison with newer drugs such as the direct oral anticoagulants. This article provides an outline of the current guidelines and a critical assessment of the efficacy and safety data supporting the recommendations for the use of aspirin in the treatment and prevention of venous thromboembolism and other cardiovascular disorders.
- Subjects :
- medicine.medical_specialty
Acute coronary syndrome
medicine.drug_class
Low molecular weight heparin
Context (language use)
Coronary artery disease
Internal medicine
medicine
Secondary Prevention
Humans
cardiovascular diseases
Myocardial infarction
Intensive care medicine
Stroke
Aspirin
business.industry
Anticoagulants
Hematology
Venous Thromboembolism
medicine.disease
Clinical trial
Primary Prevention
Cardiovascular Diseases
Cardiology
business
Platelet Aggregation Inhibitors
medicine.drug
Subjects
Details
- ISSN :
- 18792472
- Volume :
- 135
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Thrombosis research
- Accession number :
- edsair.doi.dedup.....02eee32e4f6239cb52a394cd3201865c